Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer

Aryeh Keehn, Benjamin Gartrell, Mark P. Schoenberg

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Unlike other malignancies, the death rate of bladder cancer has not declined in several decades, highlighting the need for new treatment options. In the emerging era of immunotherapy, therapeutic cancer vaccines are an attractive option to cure, control and prevent cancer. Despite this, finding a feasible and efficacious vaccine platform has proven elusive across all malignancies. Vesigenurtacel-L is the first whole cell, allogeneic vaccine intended to treat high-grade, nonmuscle invasive bladder cancer. This type of vaccine technology for bladder cancer is novel, and has the potential to be both economically and logistically feasible.

Original languageEnglish (US)
Pages (from-to)2673-2682
Number of pages10
JournalFuture Oncology
Issue number23
StatePublished - Dec 1 2016
Externally publishedYes


  • allogeneic
  • bladder cancer
  • immunotherapy
  • nonmuscle invasive
  • therapeutic vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer'. Together they form a unique fingerprint.

Cite this